bcli stock: BrainStorm Cell Therapeutics Guide

BCLI (BrainStorm Cell Therapeutics, Inc.)

bcli stock refers to the common equity ticker for BrainStorm Cell Therapeutics, Inc., a U.S.-based biotechnology company developing autologous cell therapies for neurodegenerative diseases. This article explains who the company is, what its lead product NurOwn aims to do, the clinical and regulatory status, financial and market information, corporate history and milestones, shareholder structure, and key investment considerations. It is written as a neutral, wiki-style reference and is not investment advice.

Not to be confused with any cryptocurrency or blockchain token: bcli stock denotes an equity security traded on public markets, not a crypto asset.

Overview / Summary

bcli stock is the common stock ticker used to identify BrainStorm Cell Therapeutics, Inc. in public market quotes and investor communications. The company focuses on autologous, bone marrow–derived mesenchymal stem cell therapies developed through its NurOwn platform. NurOwn is being investigated primarily for neurodegenerative indications such as amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and related conditions.

As of the dates cited below, BrainStorm has been traded on public market venues (historically including national exchanges and OTC markets). Investors in bcli stock typically include biotech-focused retail investors, institutional specialty investors, and stakeholders monitoring clinical trial and regulatory outcomes. The security has historically shown characteristics common to small-cap biotech equities: high volatility tied to clinical news, limited liquidity on OTC venues at times, and sensitivity to capital-raising announcements.

Company background

BrainStorm Cell Therapeutics was established to develop cell-based therapies for neurodegenerative disorders. The company is headquartered in the United States and conducts R&D and clinical trial activities focused on autologous mesenchymal stem cell technologies. BrainStorm’s mission centers on developing therapeutic options that could modify disease trajectories in ALS, MS, and other CNS disorders through neurotrophic factor delivery and immunomodulation mediated by patient-derived cells.

Leadership and management have included executives and scientists with experience in biotechnology development, clinical research, and regulatory interactions. Management changes, board appointments, and C-suite hires have periodically been disclosed in company press releases and SEC filings.

Corporate timeline and milestones

• Founding and early R&D: BrainStorm’s early years were devoted to preclinical development of its proprietary cell platform and initial clinical feasibility studies.
• Initial clinical programs: The company advanced NurOwn into human clinical trials, including Phase II and Phase III studies, with trial readouts and post-hoc analyses published or presented at scientific meetings.
• Public listings and market transitions: bcli stock has traded on public markets; the company has reported transitions between market venues and OTC trading at various times.
• Capital raises and financings: BrainStorm has periodically completed offerings, registered direct placements, and other financing transactions to fund clinical development and operations. Such financings have been announced via press releases and SEC filings.
• Corporate actions: The company has undertaken corporate actions reported in filings, including share issuances and, in some periods, share consolidation events described in official documents.

(For definitive dates and legal details of incorporation, capital raises, and corporate actions, consult the company’s SEC filings and investor relations archives.)

Research & development / Products

BrainStorm’s flagship platform is NurOwn, an autologous cell therapy approach that uses a patient’s own bone marrow–derived mesenchymal stem cells (MSCs) that are induced to secrete neurotrophic factors. The intent of the NurOwn manufacturing process is to expand and condition MSCs ex vivo and then administer them back to the patient with the goal of providing neuroprotective and immunomodulatory effects in the central nervous system.

Key features of the NurOwn platform:

• Autologous approach: Cells are harvested from the patient, processed and expanded in a controlled manufacturing environment, then re-administered to the same patient. Autologous therapies aim to reduce some immune-compatibility issues associated with allogeneic cells but are operationally more complex.
• Neurotrophic factor delivery: NurOwn cells are designed to produce neurotrophic factors that could support neuron survival and function in degenerative conditions.
• Indications: NurOwn has been evaluated most extensively in ALS. The company has also pursued exploratory and development activities in MS and discussed potential research in Alzheimer’s disease and related neurodegenerative conditions.

Clinical manufacturing and quality control (CMC) of an autologous cell product are central to the program and have been a focus of regulatory interactions and trial design considerations.

Clinical trial program

BrainStorm’s clinical development of NurOwn has included Phase II and Phase III studies in ALS, together with additional trials and analyses to refine endpoints, patient selection, and regulatory strategy.

• Phase II: Earlier-phase studies aimed to assess safety, tolerability, and signals of efficacy. These trials informed subsequent registrational trial design.
• Phase III: The company has completed or reported on Phase III studies, with topline and secondary endpoint data presented in company releases and scientific forums. Results have been subject to interpretation through primary analyses and post-hoc analyses.
• Post-hoc analyses and subgroup work: In some cases, post-hoc analyses suggested differential effects in subgroups or on selected endpoints, which the company highlighted in investor communications and scientific presentations.
• Ongoing and planned studies: BrainStorm has described plans for additional registrational or Phase 3b programs intended to address regulatory questions, refine primary endpoints, or demonstrate effect sizes needed for potential approvals. The company has also engaged in discussions with regulatory agencies on trial designs and CMC matters.

For specific trial identifiers, enrollment criteria, primary endpoints, and status, review clinicaltrials.gov records and the company’s clinical trial disclosures in investor materials and SEC filings.

Regulatory interactions

Regulatory engagement has been a central part of BrainStorm’s strategy for NurOwn. The company has publicly reported formal and informal communications with regulatory authorities about trial design, endpoints, and manufacturing controls.

• FDA interactions: BrainStorm has described interactions with the U.S. Food and Drug Administration (FDA) on trial design and development plans. These engagements often shape the path toward potential registrational studies.
• Special Protocol Assessments (SPA) and formal agreements: Where applicable, companies may seek SPA agreements or similar feedback regarding trial design and statistical analysis plans. BrainStorm has reported regulatory discussions and has indicated that regulatory feedback influenced clinical program adjustments.
• CMC alignment: For autologous cell therapies, chemistry, manufacturing, and controls (CMC) are critical. BrainStorm has disclosed work to align its manufacturing processes with regulatory expectations, including process controls, release testing, and patient-safety measures.

Regulatory pathways for cell therapies include complex requirements. Investors and stakeholders should consult the company’s formal filings and press releases for precise summaries of regulatory milestones and statements from regulators.

Financials and capitalization

bcli stock’s market behavior and the company’s financial profile reflect its clinical-stage biotech status. Clinical-stage companies often report limited or no product revenue and sustain net losses as they invest in R&D and trials.

As of the reporting dates in company filings and market summaries, BrainStorm’s financial statements typically included:

• Revenue profile: Historically limited product revenue; revenue (if any) derives from collaborations, milestone receipts, or other non-product sources.
• Net losses: Most of the company’s recent reported results have shown net losses driven by R&D expenses, clinical trial costs, and general corporate expenses.
• Cash and liquidity: The company periodically reports cash-on-hand and compares liquidity to near-term capital needs. BrainStorm has conducted capital raises (registered direct offerings and other transactions) to support operations.
• Debt: When present, debt instruments and their terms are disclosed in the company’s financial statements and notes.

Quantitative financial metrics change with quarterly and annual reporting. For up-to-date numeric figures (cash, operating loss, revenue, total liabilities), consult the company’s most recent 10-Q or 10-K filed with the SEC and the investor relations financial reports.

Share structure and corporate actions

Share structure details commonly reported by BrainStorm include outstanding shares, authorized share counts, and any notable share issuance or consolidation events. Corporate actions that affect share count and per-share metrics can include:

• Registered direct offerings and equity placements that increase outstanding shares and can dilute existing shareholders.
• Option and warrant exercises that change the fully diluted share count.
• Reverse stock splits or share consolidations that reduce the number of outstanding shares and adjust per-share metrics; the company reports the ratio and effective date in filings when these actions occur.

For exact outstanding share counts, the most recent SEC filing is the authoritative source. Changes in outstanding shares should be reconciled using the company’s quarterly and current filings.

Stock market information and trading

bcli stock has traded on multiple public market venues over time. Market data providers and the company’s investor resources indicate the ticker symbol and trading venues used in different periods. Investors should be aware of the trading environment and market conventions applicable to bcli stock.

• Ticker and exchanges: The company has used the ticker BCLI for its common stock. Historical trading venues have included national exchanges as well as OTC markets at various times; consult official market quotes for the current trading venue.
• Trading characteristics: Small-cap biotech stocks such as bcli stock often experience low liquidity, wider bid-ask spreads, and elevated volatility, especially around clinical announcements or financing events. OTC trading can carry additional considerations, including delayed reporting of trades and lower market depth.
• Price performance: Price ranges, 52-week highs and lows, and volatility metrics are published by market-data providers. These figures vary by source and are time-sensitive.

Market data and metrics

Investors commonly consult the following market statistics for bcli stock:

• Market capitalization: The aggregate market value of outstanding shares as reported by market-data providers on a given date.
• Average daily volume: The mean trading volume over a recent period (e.g., 30- or 90-day average) that indicates liquidity.
• Beta and volatility measures: Statistical metrics that describe how the stock’s price moves relative to broader markets.
• Short interest: The number of shares sold short as reported in market data, which can indicate bearish positioning.
• Analyst coverage and price targets: Where available, sell-side or independent analysts may provide coverage; smaller companies often have limited analyst coverage.

As of the reporting dates below, market data providers reported specific numeric metrics for bcli stock; see the Sources section and the company’s investor pages for dated figures.

Ownership and shareholder base

Ownership in bcli stock typically reflects a mix of insiders (executive officers, directors), institutional shareholders, and retail investors. Institutional holdings can include specialized biotech funds or healthcare-focused investors. Insider transactions (purchases, grants, or sales) are disclosed in SEC filings and Form 4 reports.

Retail interest in bcli stock has sometimes been visible on public discussion platforms and niche biotech communities. Institutional ownership levels and significant holders are reported periodically by market-data services and the company’s filings.

Recent news and developments

Below are representative tallies of recent public updates and press releases. Each item includes a dated reference to preserve context and timeliness.

• As of 2025-12-15, according to the company’s investor relations release, BrainStorm reported updated safety and exploratory efficacy analyses from a NurOwn clinical cohort presented at a scientific meeting. The release summarized observed outcomes and next steps for trial planning.

• As of 2025-09-30, according to a company press release, BrainStorm completed a registered direct offering to raise capital for clinical operations and manufacturing scale-up; offering details such as gross proceeds and share count changes were disclosed in the filing. The company noted the financing’s role in supporting planned registrational activities.

• As of 2025-07-20, according to investor presentations published by BrainStorm, the company outlined a proposed Phase 3b/registrational study design for NurOwn in ALS that would address prior review comments from regulators and aim to confirm clinical endpoints.

• As of 2024-11-05, market-data providers reported that bcli stock experienced elevated trading volume following public dissemination of post-hoc analyses and a management-hosted investor webinar summarizing clinical learnings and next steps.

(For precise wording, dates, numeric details, and official documents, consult the press release archive and SEC filings on the company’s investor relations site.)

Risks and investment considerations

This section highlights principal risks and considerations that are typically relevant for investors evaluating bcli stock. The points below are factual descriptions of typical risk factors; they are not investment advice.

• Clinical development risk: NurOwn is an investigational therapy. Clinical trials can fail to meet primary or secondary endpoints, and positive early signals may not translate into registrational success.
• Regulatory risk: FDA or other regulatory authorities may require additional trials, different endpoints, or CMC data sufficient to support approval. Regulatory reviews can be lengthy and uncertain.
• Binary event risk: Biotech equities often move sharply on single pieces of trial or regulatory news (so-called binary risk), which can produce rapid gains or losses.
• Financing and dilution risk: Clinical-stage companies commonly raise capital through equity offerings. Financing events dilute existing shareholders and can influence short-term share price pressure.
• Liquidity and market structure risk: bcli stock may trade on OTC markets or have low average daily volume, resulting in wider spreads and execution difficulty for large orders.
• Operational and manufacturing risk: Autologous cell therapies require robust manufacturing systems and quality controls. Difficulties in scaling or maintaining consistent product quality can delay development.
• Legal and intellectual property risk: Protection of proprietary processes, freedom-to-operate considerations, and potential litigation can affect the business.

Investors should review the company’s risk disclosures in the most recent SEC filings for a complete and authoritative list of risks.

Investor relations and disclosures

Official sources are the authoritative references for bcli stock. Investors and researchers should consult:

• The company’s investor relations site and press release archive for dated announcements and presentations.
• Quarterly and annual SEC filings (Form 10-Q, 10-K) for audited financials, risk factors, and legal disclosures.
• Current reports on Form 8-K for material events such as financings, clinical data releases, or executive changes.
• Market-data provider quotes for real-time or delayed stock prices, volume, and basic metrics.

Note on data timeliness: Market-data platforms may show delayed or slightly different numbers for market cap and price metrics. For legal or compliance use, rely on the company’s filed documents and exchange-reported trade data.

See also

• Stem cell therapy
• Autologous cell therapy
• ALS clinical trials
• OTC market trading conventions

References and sources

The information in this article is compiled from company filings, investor materials, and market-data providers. Representative sources used to compile the content include:

• BrainStorm Cell Therapeutics — Official Investor Relations materials and press releases (company IR pages)
• SEC filings (Form 10-Q, 10-K, Form 8-K and Form 4 insider transaction reports)
• Market-data providers and financial portals reporting on BCLI quotes and statistics
• ClinicalTrials.gov for trial identifiers and study status
• Scientific conference abstracts and posters where NurOwn data were presented

When numerical figures or precise dates are required, consult the original source filings and press releases for verification.